<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03199313</url>
  </required_header>
  <id_info>
    <org_study_id>Sutezolid - CL001</org_study_id>
    <nct_id>NCT03199313</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Alliance for TB Drug Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single ascending dose study conducted&#xD;
      at one study center in the United States. Four (4) cohorts of 8 subjects each (6 active and 2&#xD;
      placebo). Subjects will participate in only one cohort.&#xD;
&#xD;
      Safety will be assessed throughout the study; serial ECGs and serial blood samples will be&#xD;
      collected for the safety and PK assessment of sutezolid.&#xD;
&#xD;
      Dose escalation to the next cohort (i.e., dose level) will not take place until the Sponsor,&#xD;
      in conjunction with the Principal Investigator, has determined that adequate safety,&#xD;
      tolerability and PK from the previous cohort has been demonstrated to permit proceeding to&#xD;
      the next cohort.&#xD;
&#xD;
      Interim PK analyses will be performed for the dose escalation decisions to reconsider the&#xD;
      sampling time points as the study progresses. All samples will be sent for analysis and the&#xD;
      bioanalytical lab will be unblinded and only run the analysis on active treatment subjects.&#xD;
      Data from the analysis used for the escalation meetings will only include active treatment&#xD;
      subjects, and will be blinded by subject.&#xD;
&#xD;
      Subjects will be housed in the clinic from at least 24 hours prior (from Day -2), until 48&#xD;
      hours (Day 3) after dosing. Subjects will be contacted via a phone call for follow-up&#xD;
      questioning about adverse events 7 days later (Study Day 10).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2017</start_date>
  <completion_date type="Actual">December 16, 2017</completion_date>
  <primary_completion_date type="Actual">December 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single oral doses of sutezolid in healthy adult subjects evaluated by Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Days 0-10</time_frame>
    <description>Safety will be evaluated by Treatment Emergent Adverse Events (TEAEs) following doses of sutezolid or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of single oral doses of sutezolid using Cmax</measure>
    <time_frame>Days 0-10</time_frame>
    <description>This will be measured through PK parameters like Cmax; Cmax = maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of single oral doses of sutezolid using AUC</measure>
    <time_frame>Days 0-10</time_frame>
    <description>This will be measured through PK parameters like AUC; AUC = Area under the curve,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of single oral doses of sutezolid using Tmax</measure>
    <time_frame>Days 0-10</time_frame>
    <description>This will be measured through PK parameters like Tmax; Tmax = Time of the maximum drug concentration (obtained without interpolation)</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Sentinel Group 1 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 2, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Sentinel Group 1 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 1, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Sentinel Group 2 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 4, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Sentinel Group 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 1, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 6, 600mg sutezolid or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 2, 600mg sutezolid or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 6, 1200 mg sutezolid or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 2, 1200 mg sutezolid or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 6, 1800 mg sutezolid or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 2, 1800 mg sutezolid or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sutezolid</intervention_name>
    <description>Sutezolid supplied as tablets and matching placebo for oral administration.</description>
    <arm_group_label>Cohort 1 Sentinel Group 1 - Active</arm_group_label>
    <arm_group_label>Cohort 1 Sentinel Group 2 - Active</arm_group_label>
    <arm_group_label>Cohort 2 - Active</arm_group_label>
    <arm_group_label>Cohort 3 - Active</arm_group_label>
    <arm_group_label>Cohort 4 - Active</arm_group_label>
    <other_name>PNU-100480</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Sutezolid placebo</description>
    <arm_group_label>Cohort 1 Sentinel Group 1 - Placebo</arm_group_label>
    <arm_group_label>Cohort 1 Sentinel Group 2 - Placebo</arm_group_label>
    <arm_group_label>Cohort 2 - Placebo</arm_group_label>
    <arm_group_label>Cohort 3 - Placebo</arm_group_label>
    <arm_group_label>Cohort 4 - Placebo</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject understands study procedures and provides written, informed consent prior to&#xD;
             all trial-related procedures.&#xD;
&#xD;
          2. Healthy adult male and females of non-childbearing potential, 19 to 50 years of age&#xD;
             (inclusive) at the time of screening.&#xD;
&#xD;
          3. &lt; Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) and a body weight of no less than&#xD;
             50.0 kg.&#xD;
&#xD;
          4. Medically healthy with no clinically significant, as determined by the Investigator,&#xD;
             screening results (e.g., laboratory profiles are normal or up to Grade 1 per Division&#xD;
             of Microbiology and Infectious Diseases [DMID] Toxicity Tables) medical history, vital&#xD;
             signs, ECGs, physical examination findings. Laboratory results within the testing&#xD;
             facility's normal range will not be considered AEs when referenced to the DMID&#xD;
             assessment/grading scale. If exclusionary laboratory criteria are met, values may be&#xD;
             confirmed by repeat evaluation.&#xD;
&#xD;
          5. No use of tobacco or nicotine containing products (including smoking cessation&#xD;
             products), for a minimum of 6 months prior to dosing.&#xD;
&#xD;
          6. Females of non-childbearing potential, having undergone one of the following&#xD;
             sterilization procedures at least 6 months prior to dosing:&#xD;
&#xD;
               1. Hysteroscopic sterilization&#xD;
&#xD;
               2. Bilateral tubal ligation or bilateral salpingectomy&#xD;
&#xD;
               3. Hysterectomy&#xD;
&#xD;
               4. Bilateral oophorectomy&#xD;
&#xD;
               5. or be postmenopausal with amenorrhea for at least 1 year prior to the first dose&#xD;
                  with serum follicle stimulating hormone (FSH) levels consistent with&#xD;
                  postmenopausal status at screening.&#xD;
&#xD;
          7. Non-vasectomized males (or males vasectomized less than 120 days prior to study&#xD;
             start), must agree to the following during study participation and for 90 days&#xD;
             following the last administration of study drug:&#xD;
&#xD;
               1. use a condom with spermicide while engaging in sexual activity or be sexually&#xD;
                  abstinent&#xD;
&#xD;
               2. not donate sperm during this time. In the event the sexual partner is surgically&#xD;
                  sterile, use of a condom with spermicide is not necessary. None of the&#xD;
                  restrictions listed above are required for vasectomized males whose procedure was&#xD;
                  performed more than 120 days prior to study start.&#xD;
&#xD;
             In the event the sexual partner is surgically sterile, use of a condom with spermicide&#xD;
             is not necessary. None of the restrictions listed above are required for vasectomized&#xD;
             males whose procedure was performed more than 120 days prior to study start.&#xD;
&#xD;
          8. Willing to answer inclusion and exclusion criteria questionnaire at check-in.&#xD;
&#xD;
          9. Be able to comply with the protocol and the assessments therein, including all&#xD;
             restrictions.&#xD;
&#xD;
         10. Is willing and able to remain in the study unit for the entire duration of the&#xD;
             assigned confinement period and receive a phone call for follow-up questioning about&#xD;
             AEs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from the study if there is evidence of any of the following&#xD;
        criteria at screening or check-in, as appropriate.&#xD;
&#xD;
        Medical History&#xD;
&#xD;
          1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,&#xD;
             or psychiatric disease as determined by the Investigator to be clinically relevant.&#xD;
&#xD;
          2. History of any illness that, in the opinion of the Investigator, might confound the&#xD;
             results of the study or poses an additional risk to the subject by their participation&#xD;
             in the study.&#xD;
&#xD;
          3. Surgery within the past 90 days prior to dosing as determined by the Investigator to&#xD;
             be clinically relevant, or any history of cholecystectomy.&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within the past 2 years as determined&#xD;
             by the Investigator to be clinically relevant.&#xD;
&#xD;
          5. History of sensitivity or contraindication to use of linezolid or any study&#xD;
             investigational products.&#xD;
&#xD;
          6. Female subjects who are pregnant or lactating.&#xD;
&#xD;
          7. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
             screening.&#xD;
&#xD;
          8. Heart rate is lower than 40 bpm or higher than 99 bpm at screening.&#xD;
&#xD;
          9. Any clinically significant electrocardiogram abnormality at Screening (as deemed by&#xD;
             decision of the Investigator and the Sponsor's Medical Monitor).&#xD;
&#xD;
             NOTE: The following can be considered not clinically significant without consulting&#xD;
             the Sponsor's Medical Monitor:&#xD;
&#xD;
               1. Mild first degree A-V block (P-R interval &lt;0.23 sec)&#xD;
&#xD;
               2. Right or left axis deviation&#xD;
&#xD;
               3. Incomplete right bundle branch block&#xD;
&#xD;
               4. Isolated left anterior fascicular block (left anterior hemiblock) in younger&#xD;
                  athletic subjects&#xD;
&#xD;
         10. QTcF interval &gt;450 msec for males or &gt;470 msec for females at screening, Day -2, Day&#xD;
             -1, or Day 1 (pre-dose), or history of prolonged QT syndrome.&#xD;
&#xD;
         11. Family history of Long-QT Syndrome or sudden death without a preceding diagnosis of a&#xD;
             condition that could be causative of sudden death (such as known coronary artery&#xD;
             disease, congestive heart failure or terminal cancer).&#xD;
&#xD;
         12. History of one or any combination of, the following:&#xD;
&#xD;
               1. Seizures or seizure disorders&#xD;
&#xD;
               2. Brain surgery.&#xD;
&#xD;
               3. History of head injury in the last five years&#xD;
&#xD;
               4. Any serious disorder of the CNS or related neurological system, particularly one&#xD;
                  that may lower the seizure threshold.&#xD;
&#xD;
               5. History of seizures Specific Treatments&#xD;
&#xD;
         13. Use of any prescription medication within 14 days prior to dosing.&#xD;
&#xD;
         14. Use of any over-the-counter (OTC) medication, including herbal products and vitamins,&#xD;
             within the 7 days prior to dosing, except acetaminophen. Up to 3 grams per day of&#xD;
             acetaminophen is allowed at the discretion of the Investigator prior to dosing.&#xD;
&#xD;
         15. Use of any drugs or substances known to be significant inhibitors of Cytochrome P450&#xD;
             (CYP) enzymes and/or significant inhibitors or substrates of P-glycoprotein (P-gp)&#xD;
             and/or Organic anion transporting polypeptides (OATP) within 14 days prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
         16. Use of any drugs or substances known to be inducers of CYP enzymes and/or P-gp,&#xD;
             including St. John's Wort, within 28 days prior to the first dose of study drug.&#xD;
&#xD;
         17. Use of any drugs or substance known to lower the seizure threshold.&#xD;
&#xD;
         18. Blood donation or significant blood loss within 56 days prior to dosing.&#xD;
&#xD;
         19. Plasma donation within 7 days prior to dosing.&#xD;
&#xD;
         20. Participation in another clinical trial within 28 days prior to dosing.&#xD;
&#xD;
         21. Consumption of the following prior to dosing period:&#xD;
&#xD;
               1. Alcohol - 48 hours prior to dosing&#xD;
&#xD;
               2. Grapefruit/Mandarin Oranges - 10 Days prior to dosing&#xD;
&#xD;
               3. Caffeine/Xanthine - 24 hours prior to dosing Laboratory Abnormalities&#xD;
&#xD;
         22. Positive results for the urine drug/alcohol screen at screening or check-in.&#xD;
&#xD;
         23. Positive urine cotinine at screening.&#xD;
&#xD;
         24. Serum magnesium potassium, or calcium laboratory values outside of the normal range at&#xD;
             screening. If exclusionary lab criteria are met, values may be confirmed by repeat&#xD;
             evaluation.&#xD;
&#xD;
         25. Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B&#xD;
             Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV).&#xD;
&#xD;
         26. Is unwilling to remove any artificial nails (e.g. acrylic, gel) or fingernail polish&#xD;
             and not use such products for the duration of the study.&#xD;
&#xD;
         27. Is receiving any of the following medications: monoamine oxidase (MAO) inhibitors&#xD;
             (phenelzine, tranylcypromine), tricyclic antidepressants (amitriptyline,&#xD;
             nortriptyline, protriptyline, doxepin, amoxapine, etc.), antipsychotics such as&#xD;
             chlorpromazine and buspirone, serotonin re-uptake inhibitors (fluoxetine, paroxetine,&#xD;
             sertraline, etc.), buproprion, agents known to prolong the QTc interval (erythromycin,&#xD;
             clarithromycin, astemizole, type Ia [quinidine, procainamide, disopyramide] and III&#xD;
             [amiodarone, sotalol] anti-arrhythmics, carbamazepine, sulfonylureas, and meperidine),&#xD;
             within 30 days before the first dose of study drug or during the study drug treatment&#xD;
             period.&#xD;
&#xD;
         28. Use of any adrenergic/serotonergic agonists, such as pseudoephedrine and&#xD;
             phenylpropanolamine (frequently found in cold and cough remedies), within 7 days&#xD;
             before the first dose of study drug or during the study drug treatment period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Bruinenberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Global Alliance for TB Drug Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>TB</keyword>
  <keyword>Sutezolid</keyword>
  <keyword>pulmonary tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

